Cat. No.: HY-B0263

Thiabendazole

(Synonyms: Tiabendazole; 2-(4-Thiazolyl)benzimidazole)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Thiabendazole is an orally available benzimidazole fungicide with repellent and anticancer activities. Thiabendazole can result in developmental malformations. Thiabendazole can be used for modeling.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 148-79-8
Formula: C₁₀H₇N₃S
Molecular Weight:201.25

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Thiabendazole Chemical Structure

CAS No.: 148-79-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Thiabendazole is an orally available benzimidazole fungicide with repellent and anticancer activities. Thiabendazole can result in developmental malformations. Thiabendazole can be used for modeling^[1]^[2]^[3]^[4]^[5].

IC₅₀ & Target

CDK2

CCNE1

bax

Caspase-9

Caspase 3

IL-1β

IL-10

IL-6

IL-13

IFN-gamma

All Caspase Isoforms :

All CDK Isoforms :

All Parasite Isoforms :

All VEGFR Isoforms :

All Interleukin Related Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	50 μM Compound: TBZ	Concentration required to reduced HIV-1-induced cytopathic effect by 50% in CEM cells Concentration required to reduced HIV-1-induced cytopathic effect by 50% in CEM cells	[PMID: 12431069]
CCRF-CEM	EC₅₀	1.1 μM Compound: TBZ	Effective concentration (anti-HIV activity) required to reduce HIV-1 induced cytopathic effect by 50%in CEM cells Effective concentration (anti-HIV activity) required to reduce HIV-1 induced cytopathic effect by 50%in CEM cells	[PMID: 12431069]
CCRF-CEM	EC₅₀	1.39 μM Compound: TBZ	Anti-HIV-1 activity against mutant HIV-1 strain (HIV-1IIIB) in CEM cells Anti-HIV-1 activity against mutant HIV-1 strain (HIV-1IIIB) in CEM cells	[PMID: 12431069]
CCRF-CEM	EC₅₀	1.73 μM Compound: TBZ	Anti-HIV-1 activity against mutant HIV-1 strain (138Glu-Lys) in CEM cells Anti-HIV-1 activity against mutant HIV-1 strain (138Glu-Lys) in CEM cells	[PMID: 12431069]
CCRF-CEM	EC₅₀	13.8 μM Compound: TBZ	Anti-HIV-1 activity against mutant HIV-1 strain(181 Tyr-Cys) in CEM cells Anti-HIV-1 activity against mutant HIV-1 strain(181 Tyr-Cys) in CEM cells	[PMID: 12431069]
CCRF-CEM	EC₅₀	15.6 μM Compound: TBZ	Anti-HIV-1 activity against mutant HIV-1 strain (103Lys-Asn) in CEM cells Anti-HIV-1 activity against mutant HIV-1 strain (103Lys-Asn) in CEM cells	[PMID: 12431069]
CCRF-CEM	EC₅₀	3.12 μM Compound: TBZ	Anti-HIV-1 activity against mutant HIV-1 strain (100Leu-Ile) in CEM cells Anti-HIV-1 activity against mutant HIV-1 strain (100Leu-Ile) in CEM cells	[PMID: 12431069]
CCRF-CEM	EC₅₀	4.16 μM Compound: TBZ	Anti-HIV-1 activity against mutant HIV-1 strain(188 Tyr-His) in CEM cells Anti-HIV-1 activity against mutant HIV-1 strain(188 Tyr-His) in CEM cells	[PMID: 12431069]
HEK293	IC₅₀	>500 μM Compound: thiabendazole	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HUVEC	EC₅₀	>250 μM Compound: Thiabendazole	Antiproliferative activity against HUVEC after 30 hrs by [3H]-thymidine incorporation assay Antiproliferative activity against HUVEC after 30 hrs by [3H]-thymidine incorporation assay	[PMID: 23634668]
MT4	CC₅₀	19.2 μM Compound: TBZ	Cytotoxic concentration (anti-HIV activity) required to reduce HIV-1 induced viability by 50% in MT-4 cells Cytotoxic concentration (anti-HIV activity) required to reduce HIV-1 induced viability by 50% in MT-4 cells	[PMID: 12431069]
MT4	EC₅₀	0.352 μM Compound: TBZ	Effective concentration (anti-HIV activity) required to reduce HIV-1 induced cytopathic effect by 50% in MT-4 cells Effective concentration (anti-HIV activity) required to reduce HIV-1 induced cytopathic effect by 50% in MT-4 cells	[PMID: 12431069]
Sf9	IC₅₀	44.7 μM Compound: Thiabendazole	Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells Inhibition of human MetAP2 expressed in baculovirus infected Sf9 cells	[PMID: 20621724]

In Vitro

Thiabendazole (0/50/100/200/300/400/500 μM, 24/48/72 h) time- and dose-dependently inhibits B16F10 and B16 cells proliferation^[2].
Thiabendazole (250 μM, 16 h) inhibits angiogenesis in Xenopus embryos and disrupts newly established vasculature^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

B16F10, B16
Concentration:

0/50/100/200/300/400/500 μM
Incubation Time:

24/48/72 h
Result:

Suggested that thiabendazole exhibited inhibitory effects to murine melanoma cell lines in vitro.
The IC₅₀ values of B16 cells were 540.8, 410.7, 280.4 μM at 24, 48, and 72 h, respectively.
And the IC₅₀ values of B16F10 cells were 532.4, 322.9, 238.5 μM at 24, 48, and 72 h, respectively.

In Vivo

Thiabendazole (50 mg/kg, 27 days) slows tumor growth in a mouse Xenopus model^[3].
Thiabendazole (0/0.5/1/2/4/5/10/20/ mg/L, 0-96 hpf) induces developmental defects in zebrafish through apoptosis, oxidative stress, and changes of PI3K/Akt and MAPK pathwayssup>[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar rats (adult male, 173±4 g average weight)^[6]
Dosage:

90 mg/L, daily oral exposure for 90 days
Administration:

p.o.
Result:

Significantly changed the blood parameters in the sample.
(1) Significantly altered blood parameters in the samples.
(2) Red blood cells count and hemoglobin content were significantly reduced.
(3) Platelet count dropped significantly.
(4) The mean values of MCV (mean corpuscular volume) and MCH (mean corpuscular hemoglobin) were significantly increased.
(5) Eosinophil content was significantly reduced.
Significantly reduced the expression levels of immunoglobulins IgG and IgM.
Significantly up-regulated the inflammatory factors (TNF-α, INF-γ, IL-1β, IL-6, L-10 and IL-13) in spleen tissue.and the cytokines CD4 increased and CD8 decreased.

Animal Model:

Wild-type zebrafish (AB strain) and transgenic zebrafish models, including flk1:eGFP, olig2:dsRed, and L-fabp:dsRed;elastase:GFP)^[4]
Dosage:

0/0.5/1/2/4/5/10/20 mg/L
Administration:

Soak drug administration
Result:

None of the embryos exposed to 20 and 50 mg/L of thiamendam survived.
Induced apoptosis and cell cycle arrest in zebrafish larvae.
Reduced the expression levels of antioxidant enzymes inducing ROS production and inflammatory response.
Induced cardiovascular defects in zebrafish larvae.
Caused motor neuron toxicity in zebrafish larvae.
Caused hepatotoxicity and pancreatic toxicity.

Chemical Information

CAS No. 148-79-8
Appearance Solid
Molecular Weight 201.25
Formula C₁₀H₇N₃S
Color White to off-white
SMILES

C1(C2=CSC=N2)=NC3=CC=CC=C3N1
Synonyms

Tiabendazole; 2-(4-Thiazolyl)benzimidazole
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Emerg Contam

2026 Feb 23.
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
ACS Omega

Machine Learning for Discovery of GSK3β Inhibitors. [Abstract]

2020 Oct 12;5(41):26551-26561. PMID: 33110983

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (248.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.9689 mL

24.8447 mL

49.6894 mL

5 mM

0.9938 mL

4.9689 mL

9.9379 mL

10 mM

0.4969 mL

2.4845 mL

4.9689 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (398 KB)
- English - EN (398 KB)
- Français - FR (398 KB)
- Deutsch - DE (398 KB)
- Norwegian - NO (398 KB)
- Español - ES (398 KB)
- Swedish - SV (398 KB)
- Italian - IT (398 KB)
- Portuguese - PT (398 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Budetić M, et al. Review of Characteristics and Analytical Methods for Determination of Thiabendazole. Molecules. 2023 May 6;28(9):3926. [Content Brief]

[2]. Zhang, J., et al., Thiabendazole, a well-known antifungal drug, exhibits anti-metastatic melanoma B16F10 activity via inhibiting VEGF expression and inducing apoptosis. Pharmazie, 2013. 68(12): p. 962-8. [Content Brief]

[3]. Cha, H.J., et al., Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent. PLoS Biol, 2012. 10(8): p. e1001379. [Content Brief]

[4]. Park J, et al. Developmental defects induced by thiabendazole are mediated via apoptosis, oxidative stress and alteration in PI3K/Akt and MAPK pathways in zebrafish. Environ Int. 2023 Jun;176:107973. [Content Brief]

[5]. Elgebaly SA, et al. Thiabendazole-induced suppression of renal damage in a murine model of autoimmune disease. Am J Pathol. 1984 May;115(2):204-11. [Content Brief]

[6]. Motwadie ME, et al. Modulation of immune functions, inflammatory response, and cytokine production following long-term oral exposure to three food additives; thiabendazole, monosodium glutamate, and brilliant blue in rats. Int Immunopharmacol. 2021 Sep;98:107902. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.9689 mL	24.8447 mL	49.6894 mL	124.2236 mL
	5 mM	0.9938 mL	4.9689 mL	9.9379 mL	24.8447 mL
	10 mM	0.4969 mL	2.4845 mL	4.9689 mL	12.4224 mL
	15 mM	0.3313 mL	1.6563 mL	3.3126 mL	8.2816 mL
	20 mM	0.2484 mL	1.2422 mL	2.4845 mL	6.2112 mL
	25 mM	0.1988 mL	0.9938 mL	1.9876 mL	4.9689 mL
	30 mM	0.1656 mL	0.8282 mL	1.6563 mL	4.1408 mL
	40 mM	0.1242 mL	0.6211 mL	1.2422 mL	3.1056 mL
	50 mM	0.0994 mL	0.4969 mL	0.9938 mL	2.4845 mL
	60 mM	0.0828 mL	0.4141 mL	0.8282 mL	2.0704 mL
	80 mM	0.0621 mL	0.3106 mL	0.6211 mL	1.5528 mL
	100 mM	0.0497 mL	0.2484 mL	0.4969 mL	1.2422 mL

Thiabendazole

4 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Thiabendazole

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Pesticide Compound Library

Structurally Diverse Fragment Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Animal Drug Library

Posttranslational Modification Library

Environmental Pollutant Compound Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Thiabendazole

All Caspase Isoforms

All CDK Isoforms

All Parasite Isoforms

All VEGFR Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Thiabendazole Related Classifications

Cat. No.: HY-B0263